Transcriptional co-factor Transducin beta-like (TBL) 1 acts as a checkpoint in pancreatic cancer malignancy

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Pancreatic ductal adenocarcinoma (PDAC) is a deadly cancer with high metastatic potential and chemoresistance.
• The underlying molecular mechanisms driving PDAC progression remain largely unknown, hindering effective treatments.

Purpose of the Study:

• To investigate the role of transcriptional co-factor Transducin beta-like 1 (TBL1) in PDAC.
• To determine if TBL1 could be a therapeutic target for pancreatic cancer.

Main Methods:

• Overexpression of TBL1 was analyzed in human and murine PDAC samples.
• TBL1 was inactivated in human and mouse pancreatic cancer cells to assess its functional impact.
• Key signaling pathways, including PI3 kinase, and cellular phenotypes like proliferation, invasion, and glucose metabolism were evaluated.
• Tumor growth and chemosensitivity were assessed in vivo.

Main Results:

• TBL1 was found to be overexpressed in PDAC.
• TBL1 inactivation reduced pancreatic cancer cell proliferation, invasiveness, and glucose uptake.
• TBL1 deficiency inhibited PI3 kinase signaling, which rescued TBL1 deficiency-dependent phenotypes.
• TBL1 inactivation prevented and reversed tumor growth, enhancing chemosensitivity in vivo.
• TBL1 mRNA levels correlated with PI3 kinase levels and patient survival.

Conclusions:

• TBL1 acts as a critical checkpoint in pancreatic cancer malignancy.
• TBL1 is a potential novel molecular target for treating pancreatic ductal adenocarcinoma.